Premium
Prediction of clinically insignificant prostate cancer by detection of allelic imbalance at 6q, 8p and 13q
Author(s) -
Nakano Masataka,
Takahashi Hiroyuki,
Shiraishi Taizo,
Lu Tomoe,
Furusato Masakuni,
Wakui Shin,
Hano Hiroshi
Publication year - 2008
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/j.1440-1827.2008.02246.x
Subject(s) - loss of heterozygosity , prostate cancer , prostate , pathology , cancer , medicine , nuclear medicine , biology , allele , genetics , gene
The criterion tumor volume (TV) for clinically insignificant prostate cancer has been reported, but it differs from study to study: some have reported TV < 200 mm 3 ; others, < 500 mm 3 . The aim of the present study was to distinguish clinically insignificant cancers from significant ones using molecular biological methods. A total of 184 microscopic cancers (MC) defined as limited within a 3 mm circle and 82 main tumor (MT) nodules were selected. Thirteen microsatellite loci at 6q22, 8p23.2–23, 13q14 and 13q33 were evaluated for loss of heterozygosity (LOH). MT were subgrouped as TV ≥ 500 mm 3 or <500 mm 3 ; TV ≥ 200 mm 3 or < 200 mm 3 ; and TV < 200 mm 3 , 200 mm 3 ≤ TV < 500 mm 3 or TV ≥ 500 mm 3 ; and frequencies of LOH were compared between these three groups. Frequencies of LOH at 6q16–21, 6q22, 8p23.1, 8p23.2, 13q14 were significantly lower in MC (1.0%, 2.7%, 1.9%, 1.1% and 5.4%) than in MT (30.9%, 40.4%, 12%, 8.7% and 20.6%), but no significant differences in LOH frequency were found within each of the three TV groups, between each cut‐off. When insignificant tumor is defined as TV < 200 mm 3 or < 500 mm 3 , it should include tumors with malignant potential equivalent to larger tumors. It is suggested that in order to identify insignificant tumor within a strict safety range, TV should be set lower.